It is time to review how unlicensed medicines are used by unknown
REVIEWARTICLE
It is time to review how unlicensed medicines are used
Adam Sutherland1 & Stephen Waldek2
Received: 10 February 2015 /Accepted: 5 June 2015 /Published online: 9 July 2015
# The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract The safe and effective use of medicines is an inte-
gral part of the medicine safety agenda. We present a phenom-
enological topic review of the literature relating to the use of
unlicensed medicines (ULM). There is evidence to demon-
strate that the use of ULM is associated with increased inci-
dence of adverse drug reactions, and that despite advances in
medicine regulation and guidance from professional organisa-
tions, the use of ULM in at risk populations has not reduced.
There is also evidence to suggest that patients and their carers
are not being provided with adequate information about their
medicines and that ULM are being used where safer licensed
alternatives are available. This is contrary to the philosophy of
Bpatient-focussed care^. We conclude that organisational gov-
ernance processes and professional guidelines have not kept
pace with regulatory developments or changes in legal and
ethical understanding. We recommend that governance proce-
dures for ULM be updated across healthcare settings to ensure
that patients are involved in the decisions made about their
medicines including the regulatory status of the medicine.
This includes ensuring adequate consent is obtained from
the patient (or their advocate). We also recommend that pro-
fessional bodies clarify their position on when ULM can be
used instead of licensed medicines to ensure that licensed
medicines are used wherever possible. In the current econom-
ic environment, commissioners and clinicians must resist the
temptation to use lower-quality ULM in place of licensed ones
to cut costs. We go on to recommend areas of further research
including the extent of ULM prescribing where licensed alter-
natives exist and the geographical and social factors that in-
fluence clinician prescribing of ULM.
Keywords Pharmaceutical preparations . Unlicensed
medicines .Patient safety .Medicineregulation .Adversedrug
reactions . Professional liability
Introduction
The correct use of medicines constitutes an important part of
the quality of care and patient safety agenda. All healthcare
professionals and the organisations for which they work, need
to ensure that the procurement, prescribing, dispensing and
administration of medicines complies with best practice so
helping to ensure, effective, safe, and patient focused use of
all medicines. Within the medicines management quality and
safety agenda, one issue that needs to be addressed is the
widespread use of unlicensed medicines (ULM) in its various
guises. We have reviewed the evidence around the use of
ULM and suggest how arrangements, at all levels, might be
adapted or enforced to ensure that risks to patients from this
practice are mitigated, while still considering individual pa-
tients’ needs.
Definitions
There are three situations covered by the term ULM, and we
consider these as separate entities.
1. BOff label^ (OL) refers to a situation where a licensed
medication is used outside the terms of its licensed indi-
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administration not in the authorisation, as well as to use
outside the stipulated age ranges and administration to
patients with a cited contraindication [1, 2].
2. A Bspecials medicine^ (SM) is an unlicensed medicinal
product prepared by a licensed specials manufacturer of
an unlicensed product to meet the specific needs of
a patient at the request of an authorised healthcare
professional [3]. There is a provision in the regula-
tions to permit these manufacturers to produce
batches of these medicines providing there is data
to support and inform the physicochemical stability
of these medicines.
3. The literature considers SM and true unlicensed medi-
cines (TULM) together which can be confusing. A
TULM is defined as a medicine that is used without mar-
keting authorisation in the country of use [3]. There are
different issues around prescribing, supply, and adminis-
trating of these medicines. Therefore we will consider SM
and TULM separately.
Pharmacies are required to maintain records of the dis-
pensing of SM and TULM to ensure accountability [4].
However, prescribers have no such obligation. While
TULM use is uncommon, data is sparse because in many
cases use only comes to light when an adverse incident
occurs [5].
Methods
We reviewed published literature via PubMed, MedLine and
EmBase using the following key words—unlicensed medi-
cines, medicines regulation, medicines safety, off-label pre-
scribing, and specials medicines. In addition, we also hand-
searched references for relevant additional citations. We also
reviewed regulatory documents produced by the Medicines
and Healthcare Products Regulatory Agency (MHRA) and
European Medicine Agency (EMA) as well as guidance from
professional bodies. An internet search using the terms
Bunlicensed medicines^ and Bunregistered medicines^ was
undertaken. The references and other documents we obtained
were then used to undertake and phenomenological review of
the topic.
Results
There is substantial evidence of ULM use, mostly within pae-
diatric populations. The first empirical study was in 1996 [6]
with several subsequent publications [1, 7–10]. In 2004, the
EMA published BEvidence of harm from off-label or unli-
censed medicines in children^ [11]. This regulatory review
found, as for adults, that there was under-reporting of adverse
drug reactions (ADRs) and that this was less so with prospec-
tive data collection. Clinically apparent ADRs were more
common with ULM compared to licensed medicines. The
incidence of ADRs doubled when both clinical and laboratory
parameters of detection were used [11]. A prospective review
using BEudraVigilance^ reports (an electronic data processing
network and management system for reporting and evaluating
drug reactions [11]) demonstrated there were 820 serious
ADRs involving ULM in children between 2001 and 2002
including 361 patients who either needed hospitalisation or
where hospitalisation was lengthened; 103 children died
[11]. This report implies that the use of OL and TULM is
associated with no proper labelling (side effects, cautions,
and contraindications) and dosing instructions, making medi-
cation errors more likely. An earlier study from the UK report-
ed a significant association between ULM and ADRs in chil-
dren (RR 1.27, 95 % CI 1.21–1.34) [12]. Looking at individ-
ual reports in the paediatric population, there is some variabil-
ity in the percentage of prescriptions for ULM. A UK study
reported that 36 % of prescriptions were for ULM with the
majority being for OL use rather than TULM [1]. However, a
Finnish study over 3 weeks in three paediatric wards reported
76 % of prescriptions contained at least one ULM (66 % OL,
33 % TULM) [13], The inclusion of the neonatal intensive
care unit (NICU) contributes substantially to this result and is
confirmed by Jain and colleagues who found 50 % of pre-
scriptions in the NICU were for ULM [14]. Figures from
community-based studies reveal similar results. A Dutch
cross-sectional study found 22.7 % of prescriptions were for
ULM [15] and 28.9 % were ULM in a population-based co-
hort study [16]. A Canadian primary care study in 2012 found
a prevalence of ULM prescribing of 11 %. Of significance in
this study was that careful review of the cases revealed that
79 % of them lacked good evidence of efficacy [17].
Psychotropic and other central nervous system preparations
are common and are only included because of a patient’s
age, changes to dose, route of administration, formulation, or
indication that does not appear in the SPC. Only one report
gives details of TULM with the two most common reasons
given being a special formulation (SM) or modification of a
licensed medicine (e.g. crushing or dispersing tablets or open-
ing capsules). Examples of TULM identified by this study
include a new medicine under a special manufacturing li-
cence, a chemical used as a medicine, a medicine made from
raw materials, and an imported medicine licensed in another
country but not in the country of study [2].
Very little data is available for adults, but a recent report of
a prospective, longitudinal study from Spain in five public
hospitals over a 12-month period found 232 requests for
ULM [18]. Unlike children, the top two medicine groups pre-
scribed were monoclonal antibodies (rituximab 21.1 %) and
muscle relaxants (botulinum toxin 10.7 %). Further analysis
showed that in only 48.2 % the supporting evidence was high
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(levels 1 and 2). Significant side effects were present in 25.7%
of cases, but these were mostly predictable.
In paediatric and adult populations, we see that the level of
supporting evidence for the use of ULM is low [19, 20] and
this needs to be explored. O’Connor and Liddle, reporting on
data collected on the OL use of rituximab, state that Bthe
evidence base for this remains a challenge^ [19]. In the field
of oncology, things may be slightly better and could indicate a
method of dealing with the ULM problems. Mellor and col-
leagues reviewed all the chemotherapy protocols in their
Australian oncology centre and found that out of 448 proto-
cols, 189 (42.2 %) advocated the use of ULM, and of these,
139 (69.9 %) had a good evidence base, while a further 39
(20.6 %) were based on phase II or III clinical trial data [20].
The formulation of a medicine is extremely important.
Standing and colleagues reviewed paediatric trials and found
that in many cases, information on formulation was lacking
making the data difficult to validate [21]. They go on to point
out that splitting, cutting, and dismantling tablets or capsules
can have a significant impact on efficacy. They also
state that different formulations can give rise to very
different pharmacokinetics. Although this study was
confined to paediatrics, the same would apply to all
age groups. While OL use does not usually involve
alteration of the medicine, the use of SM and TULM
often requires reformulation or compounding of a prod-
uct where there is no evidence of bioequivalence on
which to base dose. Where a TULM is produced to
be used instead of a licensed one containing the same
substance, there is no guarantee that the unlicensed
product has the same pharmacokinetic properties or
therapeutic effect.
The literature presents problems that need to be addressed,
and there are also issues that are evident but not explicitly
included in the literature. While it is clear that the use of
ULM is widespread, both in paediatric and adult prescribing
practice, there is little written about the governance issues that
surround this practice. The General Medical Council (GMC),
in its BGood Practice Guidelines^ (2013), gives clear guide-
lines on the prescribing of ULM [22]. While stating the cir-
cumstances under which ULM can be used, it is clear that
prescribers should not use an unlicensed medicine where an
identical licensed one is available. They also state that the
prescriber must satisfy themselves on the safety and efficacy
of the medicine they choose and that a good evidence base
exists for their actions. The patient and their parent, guardian,
or carer must be given information as to why an ULM is being
prescribed and on what evidence. If the use of the medicine
outside the licence is routine—such as the use of antibiotics in
an excluded age group—then detailed information may not be
necessary, and a brief explanation may suffice. Associated
with the information, the prescriber should make adequate
records as to why the ULM is being used and that information
has been given to the patient or their parents. The whole issue
of consent when dealing with ULM is covered by GMC guid-
ance from 2008 [23]. Similar advice is also given by the
MHRA in an article written in 2009 [24]. Both documents
point out that the prescriber is responsible for all the conse-
quences of using ULM. However, responsibility also rests
with the dispenser. This means that there needs to be good
communication between the two professional groups. In hos-
pitals, this might happen through formulary committees and
pharmacists’ involvement in the multidisciplinary team.
Within the community, it is the responsibility of the dispens-
ing pharmacist to contact the prescriber and discuss any ULM
use. The roles and responsibilities of the nurse are also
recognised [25]. All relevant regulators state that there needs
to be careful monitoring for ADRs in all patients receiving
ULM [11, 20, 22], and that in many cases, such as in oncol-
ogy, the surveillance should be long term because of the pos-
sibility of very late complications [26].
Discussion
As we have demonstrated, adverse events are under reported
and this is almost certainly greater in the case of ULM use.
Therefore, pharmacovigilance becomes a serious issue and the
EMA and the MHRA emphasise this point. A landmark study
from the UK demonstrated that OL and TULM use was asso-
ciated with a significantly higher risk of an ADR in children
(relative risk 1.67, with a 25 % increase in RR for every
additional ULM prescribed) [27]. Companies marketing li-
censed products within the European Union (EU) are
obliged to have pharmacovigilance systems in place
and bear liability for the effects of their products used
by patients under the terms of the marketing authorisa-
tion [28]. While prescribers and dispensers should be
obliged to report all adverse events to the appropriate
authorities (using the Byellow card^ scheme in the UK),
with SM and TULM, there is no such obligation for
manufacturers to provide pharmacovigilance because all
product liability rests with the prescriber and the multi-
disciplinary team (MDT). Prescribers and dispensers, as
well as their organisations, should ensure that they have
adequate liability insurance to cover ADRs from ULM.
Prescribers are increasingly being asked to prescribe using
generic names for products, and there must be systems in place
to ensure that the product dispensed is one that is licensed and
not a cheaper unlicensed version. For example, in the EU, be-
taine (indicated for the treatment of homocystinuria), is avail-
able as a licensed product (Cystadane®, Orphan Europe) but in
the UK, it is possible to source a cheaper unlicensed product as
a SM. A physician prescribing betaine generically will need
assurance that the licensed version is being dispensed.
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Ethical and legal considerations
The European ethical and legal situation has been well
reviewed by Lenk and Duttge in 2014 [32]. They raised very
clear issues about communication with patients and postulate
that physicians and patients’ information needs are diametrical-
ly opposed. Patients consider the licensed status of their medi-
cines as important when making choices, whereas physicians
do not think patients need to take that into account. Among
parents of children in a German renal clinic, only 24–30 % of
parents knew the licensed status of their medicines and identi-
fied a small risk that parents would refuse unlicensed medicines
or only use them if there was no other alternative available [32].
Within a palliative care setting, only 15 % of institutions regu-
larly informed patients that they were receiving ULM and 22%
of prescribers stated that they never draw attention to the use of
anULM [33]. Quoting thework ofMartin-Latry and colleagues
on the ULM use of psychotropic medicines [34], Lenke and
colleagues were not only worried about the extent of OL pre-
scribing—97 % for anticonvulsants—but that many of the pa-
tients could be described as Bvulnerable^ yet there was no clar-
ity around patient knowledge [35]. Responsibility for safety
must consider the use of ULM as a safety issue and take ther-
apeutic decisions in partnership with patients.
Case law and local regulations are out of the remit of this
paper as these vary from country to country. However, Peter
Feldschreiber of 4 New Square Chambers, London, has writ-
ten on the topic of ULM from a UK perspective [36].
The MHRA issued a guidance note on the prescribing of
caffeine, used in the treatment of apnoea of premature infants,
to ensure that licensed products and doses were used [29]. The
MHRA moved to restrict importation of unlicensed melatonin
products after a licensed product became availabe. Melatonin is
used for sleep disorders in many conditions and several unli-
censed medications were available prior to a medicine being
licensed [30]. To avoid restricting access to products for indi-
vidual patients, the MHRA provided guidance and governance
arrangements for unlicensed formulations that could be used.
Patient considerations
There is a need for medicines to meet specific patient needs
where there are no licensed alternatives. In the UK, companies
exist that will provide SM that are often reformulations of li-
censed medicines. These are often manufactured in batches with
the pharmacy dispensing them as needed on a named patient
basis. This is commonly used for cardiovascular and neurological
medicines as well as those used for rare diseases in children (e.g.
captopril for heart failure and sodium phenylbutyrate in the man-
agement of raised ammonia levels in urea cycle disorders). This
is legitimate activity but both prescriber and dispenser need to be
aware of the potential risks and ensure that the drugs are prepared
by a licensed manufacturer and that they have appropriate
arrangements should there be an ADR. However, there are situ-
ations where care needs to be taken. Some licensed special man-
ufacturers (including NHS hospitals) manufacture their own
medicines—some of them identical to licensed products—and
sell these on to other hospitals as TULM. This can lead to great
variability in active medicine as was demonstrated in the case of
3, 4-diaminopyridine used for the treatment of Eaton-Lambert
Myaesthenic syndrome. A marketing authorisation for this (as
amifampridine phosphate, Firdapse®) was granted by the EMA
in 2014. Prior to this, a number of licensed specials companies
manufactured 3,4-diaminopyridine capsules from raw chemical.
Green and colleagues analysed samples of these for medicine
content and found large variations [31]. No sample achieved
Good Manufacturing Practice standards of 95–105 % declared
label content with some samples only reaching 22.5 % of de-
clared content and some measuring 125 % of declared content.
The same issues are faced when a pharmacist or nurse takes
a licensed medicine and reformulates it to make it more pal-
atable for a patient. Even more interestingly, what of the nurse
who crushes a tablet or opens a capsule so as to facilitate a
patient swallowing the medicine, but thereby alters the effica-
cy or other attributes of the medicine making an ADR or poor
response more likely? When these situations occur, there
needs to be discussion between the pharmacist and the pre-
scriber and administering nurse, as well as with the patient.
This is not just a problem with young children, it also occurs
with the elderly and with those with swallowing difficulties.
Multi-disciplinary team (MDT) education is essential.
Decision-making considerations
Increasingly, medicines are being used OL because innovative
indications are being identified with clear patient benefit.
Innovation is crucial to medical progress and, provided there
is good evidence for this approach, patients should not be
denied what some might term Bexperimental treatment^.
However, good clinical governance structures need to be in
place and patients need to be aware of the OL status of the
therapy they are being offered.
There is incontrovertible evidence to support the risks of
ULM in patient care. There are two strategies healthcare pro-
fessionals can deploy to mitigate these risks.
The first is about giving patients the following information,
& Is the medicine licensed for the condition they are being
treated for and is it being used in the correct dose and
formulation?
& What is the evidence that a ULM is safe, effective and best
for them?
& Is there a licensed alternative?
& What are the potential side effects and what steps will be
taken to monitor and deal with them?
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Prescribers need to be open with patients and always in-
form themwhen an ULM is being used; whether as a SM, OL,
or TULM. Healthcare professionals have a responsibility to
educate and inform patients and carers about the meaning of
terms like unlicensed and off label. They should provide ade-
quate information and assurances that includes a lay explana-
tion of the evidence behind the choice of an ULM. Pharmacist
must work collaboratively with prescribers to ensure patients’
needs are met and that only licensed medicines are used when
a generic prescription is written and there is a choice between
a licensed and unlicensed product.
The second strategy relates to the policies and procedures
that are in place to protect patients from harm caused byULM.
This is a shared responsibility between professionals
and their employing institutions; the professional bodies
such as the Royal Colleges (or their equivalent else-
where); the professional regulators such as the GMC
in the UK; and the medicines regulators such as the
MHRA and the EMA. All four need to look at their
policies and guidelines and adapt them to modern issues
around the increasing use of ULM despite new licensed
medicines coming on to market.
Governance considerations
Employing authorities need to have robust clinical governance
policies and processes in place to ensure that where ULM are
used there is an adequate evidence base, there is appropriate
patient information available, that there is good record keep-
ing and that there is consent. These policies must be readily
available [For example, the East of England NHS [37]] and
subjected to rigorous audit. The professional bodies and the
professional regulators need to cooperate to ensure that guid-
ance is consistent—preferably across the EU. The experience
of the UK sees the GMC and Royal College of Paediatrics and
Child Health guidelines differ in several areas [22, 38].
Professional bodies need to work with the medicine regulators
to make changes to the licensing processes overcoming some
of the issues. Stricter controls are needed to ensure that unli-
censed Bcopycat^ medicines are not used where a licensed
product containing the same substance is available.
Obtaining a marketing authorisation for any medicine is a
long, expensive process, and the continued use of ULM jeop-
ardises future ethical research and development. We believe
that where common practice, with proper prospective audit,
has shown a medicine to be safe and effective when used OL,
the licence should be extended without the need for formal
clinical trial evidence. We appreciate that the current regula-
tory framework does not allow for this to occur, so we advo-
cate a change in regulations to facilitate this new way of work-
ing. There are many medicines, such as low molecular weight
heparins, that are not licensed for use under a certain age yet
are prescribed safely and effectively on a daily basis, very
often as part of international consensus guidelines [39].
Extending the licence in these circumstances without having
to go through a lengthy process would be advantageous to all
concerned and would bring those products into structured
pharmacovigilance procedures. There should also be a discus-
sion between all concerned as to whether, or how, this princi-
ple could be extended to less commonly used medicines
where ULM are part of evidence-based protocols utilising
good, published, and audited evidence of safety and efficacy
as described by Mellor and colleagues [20].
The use of tranexamic acid in the management of haemor-
rhage from major trauma is a good example. It is not
licensed for this use, yet there have been reports of
patient benefit when administered within 1 h of injury
and it has been recommended by NICE [40, 41]. There
is a need for legislators and regulators to examine how
policies and procedures can be put in place to encour-
age appropriate innovation. Professional and advisory
bodies could also help by coordinating and supporting
efforts to produce and standardise robust clinical gover-
nance documentation and robust audit tools.
Summary
The use of ULM is widespread and is likely to increase, espe-
cially in the field of less common or rare diseases. In order to
ensure the safe and efficacious use of ULM, robust clinical
governance processes need to be in place with adequate infor-
mation available for patients. Healthcare providers need to
review their use of ULM ensuring that licensed medicines
are used wherever possible. Healthcare commissioners must
be aware that the fiscal pressure they apply to healthcare pro-
viders may drive poor practice with respect to the use of ULM.
Professional bodies and regulators need to review their guide-
lines and regulations ensuring that they are fit for purpose and
can facilitate the use of ULM, especially OL use, where pos-
sible to ensure that innovation and advancing medical knowl-
edge is not curtailed. Individual healthcare professionals need
to be more aware of the needs and concerns of their patients
and carers, must take steps to educate and inform them about
ULM, and ensure that where there are concerns, these are
addressed. More data is needed to help encourage these
changes, and further research is important. Finally, TULM
should not be used where a licensed alternative is available,
especially where the active compound of both is identical.
This review has also identified important areas for future
research.
& What is the true extent of ULM use and to what extent are
ULM used where a licensed alternative is known?
& What is the influence of geographical or social factors on
how healthcare providers interpret guidance? This will
help us understand clinician motivations in this field.
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& What governance structures are in place in various coun-
tries and how can they be strengthened?
& Can robust audit tools be developed to assist in monitoring
this important area of clinical practice?
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